These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 11752830)

  • 1. Fixed drug eruption to rofecoxib with cross-reactivity to sulfonamides.
    Kaur C; Sarkar R; Kanwar AJ
    Dermatology; 2001; 203(4):351. PubMed ID: 11752830
    [No Abstract]   [Full Text] [Related]  

  • 2. Rofecoxib-induced pseudoporphyria.
    Markus R; Reddick ME; Rubenstein MC
    J Am Acad Dermatol; 2004 Apr; 50(4):647-8. PubMed ID: 15034522
    [No Abstract]   [Full Text] [Related]  

  • 3. Cutaneous vasculitis induced by cyclo-oxygenase-2 selective inhibitors.
    Drago F; Brusati C; Desirello G; Cacciapuoti M; Rebora A
    J Am Acad Dermatol; 2004 Dec; 51(6):1029-30. PubMed ID: 15583611
    [No Abstract]   [Full Text] [Related]  

  • 4. Lichenoid drug eruption probably associated with rofecoxib.
    Abu-Shraie NA; Alfadley AA
    Ann Pharmacother; 2004 May; 38(5):795-8. PubMed ID: 15026562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability of cyclooxygenase 2 inhibitors and the advisability of oral challenge.
    Rodríguez M; Enrique E; Castello JV; de Mateo JA; Roca B; Malek T
    Ann Allergy Asthma Immunol; 2003 Dec; 91(6):589. PubMed ID: 14700447
    [No Abstract]   [Full Text] [Related]  

  • 6. Fixed drug eruption to rofecoxib.
    Nedorost ST; Florentino FT; Gilliam AC
    Cutis; 2002 Aug; 70(2):125-6. PubMed ID: 12234159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients.
    Senna G; Bilò MB; Antonicelli L; Schiappoli M; Crivellaro MA; Bonadonna P; Dama AR
    Eur Ann Allergy Clin Immunol; 2004 Jun; 36(6):215-8. PubMed ID: 15329003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Rofecoxib-related cutaneous vasculitis].
    Defuentes G; Lecoules S; Coutant G; Algayres JP
    Presse Med; 2005 Aug; 34(14):1007-8. PubMed ID: 16225254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urticaria and angioedema from cyclooxygenase-2 inhibitors.
    Kelkar PS; Butterfield JH; Teaford HG
    J Rheumatol; 2001 Nov; 28(11):2553-4. PubMed ID: 11708434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma.
    Stevenson DD; Simon RA
    J Allergy Clin Immunol; 2001 Jul; 108(1):47-51. PubMed ID: 11447381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GI events leading to death in association with celecoxib and rofecoxib.
    Weaver J; Bonnel RA; Karwoski CB; Brinker AD; Beitz J
    Am J Gastroenterol; 2001 Dec; 96(12):3449-50. PubMed ID: 11774975
    [No Abstract]   [Full Text] [Related]  

  • 12. Acute onset of neutrophilic dermatosis in patients after therapy with a COX-2-specific inhibitor.
    Smith KJ; Skelton H
    Int J Dermatol; 2003 May; 42(5):389-93. PubMed ID: 12755981
    [No Abstract]   [Full Text] [Related]  

  • 13. Celecoxib- and rofecoxib-induced delirium.
    Macknight C; Rojas-Fernandez CH
    J Neuropsychiatry Clin Neurosci; 2001; 13(2):305-6. PubMed ID: 11449042
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety of nimesulide, meloxicam and rofecoxib as alternative analgesics.
    Karakaya G; Kalyoncu AF
    Allergol Immunopathol (Madr); 2000; 28(6):319-21. PubMed ID: 11269899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rofecoxib, Merck, and the FDA.
    Wolfe MM
    N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625749
    [No Abstract]   [Full Text] [Related]  

  • 16. What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex).
    Wooltorton E
    CMAJ; 2002 Jun; 166(13):1692-3. PubMed ID: 12126328
    [No Abstract]   [Full Text] [Related]  

  • 17. Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib.
    Sánchez-Borges M; Caballero-Fonseca F; Capriles-Hulett A
    Ann Allergy Asthma Immunol; 2005 Jan; 94(1):34-8. PubMed ID: 15702813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse oral reactions associated with the COX-2 inhibitor rofecoxib.
    Bagán JV; Thongprasom K; Scully C
    Oral Dis; 2004 Nov; 10(6):401-3. PubMed ID: 15533219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tolerability of a selective cyclooxygenase-2-inhibitor (rofecoxib) in patients with intolerance reactions to nonsteroidal anti-inflammatory agents].
    Zollner TM; Ahlbach S; Kaufmann R; Boehncke WH
    Dtsch Med Wochenschr; 2001 Apr; 126(14):386-8. PubMed ID: 11332239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reflections on the withdrawal of rofecoxib.
    Dalby AJ
    Cardiovasc J S Afr; 2005; 16(1):5-6. PubMed ID: 15562323
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.